Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

“Promising” Trend: FDA Acts On Unapproved Drugs, Tainted Supplements

This article was originally published in The Tan Sheet

Executive Summary

U.S. Marshals' seizure of unapproved erectile dysfunction drugs from Shangai Distributors may be evidence of a promising trend of FDA following through on warning letters to companies marketing unapproved new drugs mislabeled as supplements, according to food and drug attorney Marc Ullman

You may also be interested in...



Hi-Tech Prosecution Offers FDA Model For Pursuing Bad Actors – Lawyer

The successful prosecution of Hi-Tech Pharmaceuticals for counterfeiting generic Rx drugs should encourage FDA to pursue criminal charges against other companies selling adulterated products, according to food and drug attorney Marc Ullman

Hi-Tech Prosecution Offers FDA Model For Pursuing Bad Actors – Lawyer

The successful prosecution of Hi-Tech Pharmaceuticals for counterfeiting generic Rx drugs should encourage FDA to pursue criminal charges against other companies selling adulterated products, according to food and drug attorney Marc Ullman

Hi-Tech Prosecution Offers FDA Model For Pursuing Bad Actors – Lawyer

The successful prosecution of Hi-Tech Pharmaceuticals for counterfeiting generic Rx drugs should encourage FDA to pursue criminal charges against other companies selling adulterated products, according to food and drug attorney Marc Ullman

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS101557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel